{"schema_version":"secwatch.filing_event.v1","accession":"0001551152-25-000036","form_type":"8-K","ticker":"ABBV","cik":"0001551152","company_name":"AbbVie Inc.","filed_at":"2025-07-31T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.302675+00:00","generated_at":"2026-05-17T22:18:41.977763+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"AbbVie Q2 adjusted EPS $2.97 (+12.1%); raises FY 2025 guidance to $11.88-$12.08","bullets":["Q2 GAAP EPS $0.52 (down 32.5%); adjusted EPS $2.97 (+12.1%); revenue $15.423B (+6.6%).","Immunology revenue $7.631B (+9.5%); Skyrizi $4.423B (+62.2%), Rinvoq $2.028B (+41.8%), Humira $1.180B (-58.1%).","FY 2025 adjusted EPS guidance raised from $11.67-$11.87 to $11.88-$12.08; includes $0.55 IPR&D impact.","Agreed to acquire Capstan Therapeutics (anti-CD19 CAR-T for autoimmune diseases); terms not disclosed.","FDA approved Rinvoq for giant cell arteritis; Emrelis accelerated approval for c-Met high NSCLC."],"urls":{"canonical":"https://secwatch.observer/filing/0001551152-25-000036","json":"https://secwatch.observer/filing/0001551152-25-000036.json","markdown":"https://secwatch.observer/filing/0001551152-25-000036.md","text":"https://secwatch.observer/filing/0001551152-25-000036.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1551152/000155115225000036/0001551152-25-000036-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1551152/000155115225000036/abbv-20250731.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T22:18:41.977763+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}